The first phase of the AIDS vaccine yielded significant results: 97% of the immune responses were made

According to the online edition of Medical Express, the International
Vaccine Initiative Association (IAVI) and the Scripps Institute announced Wednesday local time that the first phase of clinical trials of a new
virus vaccine has produced promising results -- 97 percent of the vaccinated participants found targeted immune responses.is a disease that has not yet been cured and prevented, and its pathogen, HIV, infects and kills immune system cells, including T-cells and macrophages. HIV, as an RNA virus, has a higher frequency of mutations in its genome. After more than 30 years of research, no effective HIV vaccine or treatment has been found.
the new HIV vaccine, which successfully stimulated the production of rare immune cells (needed to start producing antibodies and fight fast-mutating viruses), clinical trials have shown that 97 percent of vaccinated participants have found targeted immune responses.William Shuif, an immunologist at the Scripps Institute and a developer of the
vaccine, said they had assumed years ago that in order to induce the emergence of "broad neutralization antibodies" (bnAbs), the process must begin by triggering the right B cells, which are specific and have the potential to develop into cells that secrete "wide neutral antibodies".
"broad neutralization antibodies" can attach to prickly proteins on the surface of HIV particles, bind to very important but "hard-to-access" areas that then fail, and these areas do not change much even between different HIV strains. This time, the team activated the correct B-cells, confirming that vaccine immunogens have the ability to do so.
researchers said the study demonstrated a "new vaccine concept for HIV" that could also be applied to other pathogens. Dennis Bouton, an immunologist and microbiologist at the Scripps Institute, says this is a huge achievement in the entire field of vaccine science - not just for the
virus, but also for vaccines for other challenging pathogens such as influenza, malaria, dengue and hepatitis viruses.
McElras, director of the Fred Hutchinson Cancer Research Center, said there has been a landmark study in the field of the
virus vaccine that has shown that it is feasible to induce "broadly mediated antibodies" to fight HIV infection.